Discover more insights into Refractory Multiple

Refractory Multiple sentence examples within chimeric antigen receptor



The Cancer-Immunity Cycle in Multiple Myeloma



Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient


Refractory Multiple sentence examples within cell maturation antigen



Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy.



Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study


Refractory Multiple sentence examples within progression free survival



Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma



Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.



Learn more from Refractory Multiple


Refractory Multiple sentence examples within belantamab mafodotin belamaf



Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.



ASH Highlights and Commentary: Multiple Myeloma


Refractory Multiple sentence examples within heavily pretreated relapsed



Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.



Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma


Refractory Multiple sentence examples within autologous stem cell



Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma



Conditioning Regimen [High-Dose Melphalan (HDM) Versus an Alternative] May Impact Response in Patients (pts) with Relapsed Multiple Myeloma (rMM) Receiving a Second Autologous Stem Cell Transplant (AutoSCT)


Refractory Multiple sentence examples within newly diagnosed multiple



Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens



Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma


Refractory Multiple sentence examples within year old man



Belantamab-mafodotin



Daratumumab/dexamethasone/pomalidomide


Refractory Multiple sentence examples within phase 3 trial



Are treatment response assessment maps (TRAMs) and 18F‐choline positron emission tomography the future of central nervous system lymphoma imaging?



Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.


Refractory Multiple sentence examples within irreversible proteasome inhibitor



Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressure



Treatment Outcomes and Toxicity Profile of Carfilzomib in Multiple Myeloma: A Single Institution Experience


Refractory Multiple sentence examples within agent belantamab mafodotin



DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma



Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.


Refractory Multiple sentence examples within year old woman



[Myelomatous meningioma: a case report].



Simultaneous therapy-related acute myeloid leukemia and relapse/refractory multiple myeloma: a therapeutic dilemma


Refractory Multiple sentence examples within autoleucel cilta cel



Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations



Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma


Refractory Multiple sentence examples within low dose dexamethasone



Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study



SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.


Refractory Multiple sentence examples within second generation proteasome



KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.



A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China


Refractory Multiple sentence examples within stem cell transplantation



Eosinophilic fasciitis (Shulman syndrome), a rare entity and diagnostic challenge, as a manifestation of severe chronic graft-versus-host disease: a case report



[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation].


Refractory Multiple sentence examples within ixazomib lenalidomide dexamethasone



[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].



Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.


Refractory Multiple sentence examples within triple class exposed



KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma



Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.


Refractory Multiple sentence examples within vicleucel ide cel



Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.



Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma


Refractory Multiple sentence examples within proteasome inhibitor carfilzomib



Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension


Refractory Multiple sentence examples within Relapsed Refractory Multiple



Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy.



Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.


Refractory Multiple sentence examples within Clas Refractory Multiple



Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor



Bispecific Antibodies in Multiple Myeloma: Present and Future.


Refractory Multiple sentence examples within Relapse Refractory Multiple



Randomized Controlled Trials versus Single Cohort Studies in Relapse Refractory Multiple Myeloma



Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations


Refractory Multiple sentence examples within refractory multiple myeloma



Real-World Treatment of Patients With Relapsed/Refractory Myeloma.



Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.


Refractory Multiple sentence examples within refractory multiple sclerosi



Therapeutic plasma exchange in MS refractory relapses: Long-term outcome.



Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy


More Refractory Multiple sentence examples
10.1016/j.clml.2021.01.018

Real-World Treatment of Patients With Relapsed/Refractory Myeloma.


More Refractory Multiple sentence examples
10.1080/10428194.2021.1941927

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.



Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features


More Refractory Multiple sentence examples
10.1007/s00277-021-04522-y

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)



Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime



Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety



Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report


More Refractory Multiple sentence examples
10.1038/s41375-021-01262-w

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma



Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).



Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond



Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis



Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens



Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis


More Refractory Multiple sentence examples
10.1158/1538-7445.AM2021-1372

Abstract 1372: Model based approach to evaluate Isatuximab (Isa) monthly dosing regimen in relapsed/refractory multiple myeloma (RRMM)



Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen


More Refractory Multiple sentence examples
10.1016/j.clml.2021.02.004

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.


More Refractory Multiple sentence examples
10.17749/2070-4909/farmakoekonomika.2021.098

Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting


More Refractory Multiple sentence examples
10.1182/bloodadvances.2019001059

Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma.



ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations


More Refractory Multiple sentence examples
10.1080/10428194.2021.1876864

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma


More Refractory Multiple sentence examples
10.21203/rs.3.rs-593228/v1

A Case of Multiple Recurrences of Trigeminal Neuralgia: Attributed to Central Sensitization?


More Refractory Multiple sentence examples
10.3760/cma.j.issn.0253-2727.2021.01.006

[The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].


More Refractory Multiple sentence examples
10.1016/j.msard.2021.103168

Therapeutic plasma exchange in MS refractory relapses: Long-term outcome.


More Refractory Multiple sentence examples
10.1016/j.clml.2021.06.020

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.


More Refractory Multiple sentence examples
10.1016/J.ACTAMAT.2021.117233

Defect accumulation and evolution in refractory multi-principal element alloys



Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study


More Refractory Multiple sentence examples
10.1007/s40278-021-94487-x

Amiodarone/phenytoin/thalidomide


More Refractory Multiple sentence examples
10.1200/JCO.2021.39.15_SUPPL.E20039

Recent updates on three drug combination regimen for relapsed refractory multiple myeloma.



Splenectomy for haemophagocytic lymphohistiocytosis of unknown origin: risks and benefits in 21 patients


More Refractory Multiple sentence examples
10.1158/2643-3230.BCD-21-0073

Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma.


More Refractory Multiple sentence examples
10.1080/17474086.2021.1886073

Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple


More Refractory Multiple sentence examples
10.1080/13696998.2020.1867469

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.



Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors



Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review


More Refractory Multiple sentence examples
10.1136/EJHPHARM-2021-EAHPCONF.104

4CPS-272 Pharmacist role in health outcome of VD-PACE savage regimen in an adult female patient with rare relapsed and refractory IgD lambda multiple myeloma


More Refractory Multiple sentence examples
10.1007/s00277-021-04534-8

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US


More Refractory Multiple sentence examples
10.1080/16078454.2021.1965737

3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.


More Refractory Multiple sentence examples
10.1016/S0140-6736(21)00592-4

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial


More Refractory Multiple sentence examples
10.1186/s12885-020-07732-1

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice


More Refractory Multiple sentence examples
10.21203/rs.3.rs-818673/v1

Patient Perspectives on Symptoms, Health-Related Quality of Life, and Treatment Experience Associated with Relapsed/Refractory Multiple Myeloma



Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation – a case series


More Refractory Multiple sentence examples
10.1007/s12288-021-01461-6

Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India


More Refractory Multiple sentence examples
10.1016/j.clml.2021.06.003

Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.



Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation


More Refractory Multiple sentence examples
10.3390/curroncol28010063

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects



Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond



Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.


More Refractory Multiple sentence examples
10.1177/20406207211027463

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma


More Refractory Multiple sentence examples
10.11406/rinketsu.62.1149

[Treatment strategies for longer life of patients with transplant-ineligible multiple myeloma].


More Refractory Multiple sentence examples
10.1200/JCO.2021.39.15_SUPPL.8021

High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.


Learn more from Refractory Multiple


Refractory Multiple
Encyclopedia